Precision BioSciences (NASDAQ:DTIL) Shares Up 3.8% – Still a Buy?

by · The Markets Daily

Precision BioSciences, Inc. (NASDAQ:DTIL – Get Free Report)’s share price shot up 3.8% on Thursday . The stock traded as high as $8.24 and last traded at $8.18. 600,930 shares traded hands during mid-day trading, an increase of 19% from the average session volume of 503,447 shares. The stock had previously closed at $7.88.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on DTIL shares. Oppenheimer began coverage on Precision BioSciences in a report on Tuesday, June 9th. They set an “outperform” rating and a $20.00 price objective for the company. Jefferies Financial Group reiterated a “buy” rating and set a $19.00 target price on shares of Precision BioSciences in a research note on Friday, March 13th. Weiss Ratings raised Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Precision BioSciences in a research note on Wednesday, May 27th. Finally, JonesTrading reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Precision BioSciences in a report on Friday, April 17th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Precision BioSciences has an average rating of “Moderate Buy” and a consensus price target of $32.25.

Read Our Latest Research Report on Precision BioSciences

Precision BioSciences Stock Up 3.8%

The company has a current ratio of 14.02, a quick ratio of 14.02 and a debt-to-equity ratio of 0.29. The firm has a market cap of $211.04 million, a price-to-earnings ratio of -2.23 and a beta of 1.25. The firm’s 50 day simple moving average is $7.12 and its two-hundred day simple moving average is $5.69.

Precision BioSciences (NASDAQ:DTIL – Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.09). Precision BioSciences had a negative return on equity of 85.37% and a negative net margin of 96.73%.The business had revenue of $10.84 million for the quarter, compared to analyst estimates of $4.05 million. On average, equities analysts forecast that Precision BioSciences, Inc. will post -2.21 EPS for the current year.

Hedge Funds Weigh In On Precision BioSciences

Hedge funds have recently added to or reduced their stakes in the stock. HBK Sorce Advisory LLC bought a new position in shares of Precision BioSciences in the fourth quarter worth $38,000. Engineers Gate Manager LP bought a new stake in Precision BioSciences during the fourth quarter worth about $43,000. Occudo Quantitative Strategies LP acquired a new stake in Precision BioSciences during the fourth quarter worth about $52,000. Miller Financial Services LLC increased its holdings in Precision BioSciences by 50.0% in the 4th quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock valued at $62,000 after buying an additional 5,000 shares during the period. Finally, Virtu Financial LLC bought a new position in Precision BioSciences in the 3rd quarter valued at about $84,000. Institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

(Get Free Report)

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.

Featured Articles